Combination therapy with an anti-hyaluronan agent and therapeutic agent

Patent metadata

Field	Value
Publication number	US-9913822-B2
Application number	US-201313815804-A
Country	US
Kind code	B2
Filing date	Mar 15, 2013
Priority date	Apr 4, 2012
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.

First claim

What is claimed:

1. A combination, comprising:
a) a composition comprising a soluble PEGylated PH20 hyaluronidase; wherein the PH20 hyaluronidase comprises an amino acid sequence that has at least 95% sequence identity to the sequence set forth in SEQ ID NO: 4; and
b) a composition comprising a tumor-targeted taxane that is nab-paclitaxel or nab-docetaxel.

2. The combination of claim 1 , wherein:
the compositions are formulated for direct administration;
the concentration of hyaluronidase is sufficient to degrade tumor-associated hyaluronan; and
the concentration of tumor-targeted taxane is sufficient to achieve intratumoral delivery of the taxane.

3. The combination of claim 1 , wherein the concentration of tumor-targeted taxane is sufficient to reduce intratumoral nucleoside deaminase protein levels or protein activity compared to the levels or activity of the nucleoside deaminase in the absence of the intratumoral taxane formulation.

4. The combination of claim 1 , wherein the hyaluronidase and tumor-targeted taxane are co-formulated for administration in a single composition.

5. The combination of claim 1 , further comprising a composition comprising a nucleoside analog, or prodrug thereof, that is a chemotherapeutic agent.

6. The combination of claim 5 , wherein:
the composition is formulated for direct administration; and
the concentration of nucleoside analog is sufficient to achieve intratumoral delivery.

7. The combination of claim 5 , wherein the nucleoside analog or prodrug thereof is provided separately from the hyaluronidase and tumor-targeted taxane.

8. The combination of claim 5 , wherein the nucleoside analog or prodrug thereof is co-formulated with one or both of the hyaluronidase and the tumor-targeted taxane.

9. The combination of claim 1 , wherein the compositions are formulated for multiple dosage administration.

10. The combination of claim 1 , wherein the compositions are formulated for single dosage administration.

11. The combination of claim 1 , wherein:
the hyaluronidase composition contains between or about between 0.5 μg to 50 mg hyaluronidase conjugated to a polymer; or
the hyaluronidase composition contains between or about between 150 Units (U) to 60,000 U hyaluronidase conjugated to a polymer.

12. The combination of claim 11 , wherein the volume of the composition containing the hyaluronidase is between or about between 0.5 mL to 100 mL.

13. The combination of claim 1 , wherein the hyaluronidase is a PH20 that is a truncated human PH20, a bovine PH20 or an ovine PH20.

14. The combination of claim 1 , wherein:
the hyaluronidase is a truncated human PH20;
the hyaluronidase is neutral active and soluble; and
the truncated PH20 comprises an amino acid sequence that contains a contiguous amino acid sequence, including at least amino acids 36-464 of SEQ ID NO:1 and terminates at a residue selected from 477, 478, 479, 480, 481, 482 or 483, or consists of an amino acid sequence that has at least 98% sequence identity to the polypeptide of SEQ ID NO:48.

15. The combination of claim 1 , wherein the PH20 comprises the amino acid sequence set forth in any of SEQ ID NOS: 4-9, 47, 48, 150-170, 183-189, or an amino acid sequence that has at least 98% sequence identity to an amino acid sequence set forth in any of SEQ ID NOS: 4-9, 47, 48, 150-170, 183-189 and retains hyaluronidase activity.

16. The combination of claim 1 , wherein:
the tumor-targeted taxane is formulated as a delivery vehicle selected from among a micelle, nanoparticle, microsphere, liposomes or hydrogel; and
the delivery vehicle is linked directly or indirectly to a tumor targeting moiety.

17. The combination of claim 1 , wherein the tumor-targeted taxane composition contains a concentration of tumor-targeted taxane that is between or about between 0.01 mg taxane/mL to 100 mg/mL.

18. The combination of claim 17 , wherein the volume of the composition comprising a tumor targeted taxane is between or about between 0.5 mL to 100 mL.

19. The combination of claim 5 , wherein the nucleoside analog is a purine or pyrimidine analog or derivatives thereof.

20. The combination of claim 19 , wherein the nucleoside analog is selected from among fluoropyrimidine 5-fluorouracil, 5-fluoro-2′-deoxycytidine, cytarabine, gemcitabine, troxacitabine, decitabine, Azacytidine, pseudoisocytidine, Zebularine, Ancitabine, Fazarabine, 6-azacytidine, capecitabine, N 4 -octadecyl-cytarabine, elaidic acid cytarabine, fludarabine, cladribine, clofarabine, nelarabine, forodesine, and pentostatin, or derivatives thereof.

21. The combination of claim 5 , wherein the nucleoside analog composition comprises a concentration of nucleoside analog that is between or about between 1 mg nucleoside analog/ml to 500 mg/ml, 5 mg/mL to 100 mg/ml, 10 mg/mL to 50 mg/mL, 25 mg/mL to 200 mg/mL or 20 mg/mL to 100 mg/mL.

22. The combination of claim 21 , wherein the volume of the composition comprising a nucleoside analog is between or about between 0.5 mL to 1000 mL.

23. The combination of claim 1 , wherein the composition(s) is (are) formulated for administration orally, intravenously (IV), subcutaneously, intramuscularly, intra-tumorally, intradermally, topically, transdermally, rectally, intrathecally or sub-epidermally.

24. The combination of claim 1 , wherein the PEGylation moiety is selected from among polyethylene glycols (PEGs) and methoxypolyethylene glycols (mPEGs).

25. The combination of claim 1 , wherein the PEGylation moiety is selected from among methoxypolyethylene glycols (mPEGs).

26. The combination of claim 1 , wherein the PEGylation moiety is a PEG, and the PEG is a branched or linear PEG.

27. The combination of claim 1 , wherein the PEGylation moiety is produced by reaction with methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (5 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (30 kDa); methoxy-poly(ethylene glycol)-succinimidyl α-methylbutanoate (mPEG-SMB) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl α-methylbutanoate (mPEG-SMB) (30 kDa); methoxy-poly(ethylene glycol)-butyraldehyde (mPEG-butyraldehyde) (30 kDa), methoxy -poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (20 kDa); methoxy -poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (30 kDa); (methoxy -poly(ethylene glycol)) 2 -N-hydroxysuccinimide ester (mPEG 2 -NHS) (10 kDa branched); methoxy-poly(ethylene glycol)) 2 -N-hydroxysuccinimide ester (mPEG 2 -NHS) (20 kDa branched); (methoxy-poly(ethylene glycol)) 2 -N-hydroxysuccinimide ester (mPEG 2 -NHS) 40 kDa branched); (methoxy-poly(ethylene glycol)) 2 -N-hydroxysuccinimide ester (mPEG 2 -NHS) (60 kDa branched); biotin-poly(ethylene glycol)-N-hydroxysuccinimide ester (biotin-PEG-NHS) (5 kDa biotinylated); poly(ethylene glycol)-p-nitrophenyl carbonate (PEG-p-nitrophenyl-carbonate) (30 kDa); or poly(ethylene glycol)-priopionaldehyde (PEG-propionaldehyde) (30 kDa).

28. The combination of claim 1 that is packaged as a kit and optionally includes instructions for use.

29. The combination of claim 5 , wherein the soluble PH20 hyaluronidase consists of the amino acid sequence set forth in any of SEQ ID NOS: 4-9, 47, 48, 150-170, 183-189, or an amino acid sequence that exhibits at least 98% sequence identity to an amino acid sequence

Assignees

• Maneval Daniel C
• Shepard H Michael
• Thompson Curtis B
• Halozyme Inc

Inventors

• Maneval Daniel C
• Shepard H Michael
• Thompson Curtis B

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title

• A61K38/47 Primary

  acting on glycosyl compounds (3.2), e.g. cellulases, lactases · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title